←
Julia Rotow MD26 posts
Julia Rotow MD avatar✓

Julia Rotow MD ✓

@JuliaRotow

Clinical Director, Lowe Center for Thoracic Oncology @DanaFarber Assistant Professor, Harvard Medical School #NSCLC #EGFR

◷ Joined February 2016▧ 6 Photos and videos
Julia Rotow MD avatar
Julia Rotow MD@JuliaRotow·Oct 6

Join us on November 2nd for the annual DFCI EGFR Center Patient and Caregiver Forum, details and register below!

Post attachmentPost attachment
Julia Rotow MD avatar
Julia Rotow MD@JuliaRotow·21 Oct 2025

The DFCI EGFR Center’s annual patient and caregiver forum is next month. Register to attend through the link below - we hope you can join us!

Post attachmentPost attachment
IDEOlogy Health avatar
⟳ Julia Rotow MD retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: Phase III HARMONi‑6 shows ivonescimab + chemo outperformed tislelizumab + chemo in first‑line squamous NSCLC, with superior PFS and comparable safety. How practice‑changing do you consider these results?

IDEOlogy Health avatar
⟳ Julia Rotow MD retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: Given the FLAURA2 exploratory analysis showing that osimertinib plus chemo improved OS across all major poor-prognosis subgroups, how likely are you to use the combination therapy as standard first-line treatment in these populations?

IDEOlogy Health avatar
⟳ Julia Rotow MD retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: Based on results from BEAMION-1 LUNG-2 cohort 2, which showed a 77% objective response rate and 96% disease control rate in untreated HER2-mutated NSCLC, how likely are you to recommend zongertinib as initial therapy over standard chemotherapy for these patients?

Julia Rotow MD avatar
Julia Rotow MD@JuliaRotow·29 May 2025

Follow us at the DFCI EGFR Center for updates on emerging data from #ASCO25 @DFEGFRcenter #NSCLC #EGFR OptiTROP-Lung03: sac-TMT NeoADAURA: neoadj osi/chemo HERTHENA-Lung02: HER3-DXd vs doublet Temab-A MET ADC SACHI: osi/savolitinib MET+ Zipalertinib and BAY2927088 EGFR ex20ins+

Julia Rotow MD avatar
Julia Rotow MD@JuliaRotow·25 May 2022

I am excited to announce I will be presenting at PER’s NSCLC satellite symposium during #ASCO22 in Chicago. Join us for dinner at 6:30 pm CT and then an in-depth, expert review of NSCLC treatments and clinical trials. Register now: https://t.co/wJP6tC0u1V #LCSM #NSCLC

Post attachment
Julia Rotow MD avatar
Julia Rotow MD@JuliaRotow·4 Jun 2021

A7 Progress at ASCO is always inspiring. Advances in targeted therapies, immunotherapies, and early diagnosis have helped to improve 5-year survival rates for NSCLC, up by 13% in the last five years. #AskReuters #ASCO2021

Julia Rotow MD avatar
Julia Rotow MD@JuliaRotow·4 Jun 2021

A6 Progress in #EGFR exon 20ins NSCLC – a subset lacking targeted therapy options until recently. Now FDA approval of amivantamab and emerging data for exon 20 inhibitors like DZD9008, with a response rate of 48% reported by James Yang at #ASCO2021 (Abstract 9008) #AskReuters

Julia Rotow MD avatar
Julia Rotow MD@JuliaRotow·4 Jun 2021

Q3 We see the stigma in society’s attitudes towards this diagnosis and in a paucity of public and private funding compared to other common cancer diagnoses. Though lung cancer is the #1 cause of cancer mortality, funding lags that of other diseases #AskReuters

Post attachment